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Myeloid differentiation factor 88 (MyD88) is an essential adaptor protein in the Toll-like receptor-mediated
innate signaling pathway, as well as in interleukin-1 receptor (IL-1R) and IL-18R signaling. The importance
of MyD88 in the regulation of innate immunity to microbial pathogens has been well demonstrated. However,
its role in regulating acquired immunity to viral pathogens and neuropathogenesis is not entirely clear. In the
present study, we examine the role of MyD88 in the CD4 T-cell response following lymphocytic choriomen-
ingitis virus (LCMV) infection. We demonstrate that wild-type (WT) mice developed a CD4 T-cell-mediated
wasting disease after intracranial infection with LCMV. In contrast, MyD88 knockout (KO) mice did not
develop wasting disease in response to the same infection. This effect was not the result of MyD88 regulation of IL-1
or IL-18 responses since IL-1R1 KO and IL-18R KO mice were not protected from weight loss. In the absence of
MyD88, naïve CD4 T cells failed to differentiate to LCMV-specific CD4 T cells. We demonstrated that MyD88 KO
antigen-presenting cells are capable of activating WT CD4 T cells. Importantly, when MyD88 KO CD4 T cells
were reconstituted with an MyD88-expressing lentivirus, the rescued CD4 T cells were able to respond to LCMV
infection and support IgG2a antibody production. Overall, these studies reveal a previously unknown role of
MyD88-dependent signaling in CD4 T cells in the regulation of the virus-specific CD4 T-cell response and in viral
infection-induced immunopathology in the central nervous system.
Myeloid differentiation factor (MyD88) is an essential adap-
tor molecule in all Toll-like receptor (TLR) signaling pathways
except TLR3. In addition, MyD88 is also important for inter-
leukin-1 receptor (IL-1R)/IL18R-mediated signaling. Many
studies have demonstrated the importance of MyD88-depen-
dent signaling in the regulation of innate as well as acquired
immunity, in particular, T-cell responses, to various microbial
pathogens (1, 2, 37, 39, 44). Although it is not entirely clear
how innate MyD88-dependent signaling regulates the activa-
tion of T-cell responses, it has been suggested that MyD88
expression in antigen-presenting cells (APCs), including den-
dritic cells (DCs), plays a key role in the activation of T-cell
responses (2, 15, 27, 39). Additionally, very recent studies have
revealed an important role of MyD88 expression in T cells in
regulating T-cell activation and pathogenesis in response to
model antigens or parasites (11, 26). However, it is not known
whether MyD88 expression in T cells plays a similar role in the
activation of T cells and regulation of pathogenesis in response
to a virus.
Lymphocytic choriomeningitis virus (LCMV) is a noncyto-
lytic virus, and most of the diseases associated with LCMV
infection in mice are mediated by either innate or acquired
immune responses. It has been well demonstrated that both
CD8 and CD4 T cells play a role in LCMV-associated
diseases, i.e., CD8 T-cell-mediated meningitis (3, 8) or CD4
T-cell-mediated weight loss (14, 21). In the absence of both
CD8 and CD4 T cells, mice do not develop symptoms fol-
lowing intracranial LCMV infection (29, 51). Thus, LCMV is a
suitable model to evaluate the contribution of a variety of
signaling molecules in the activation of CD4 as well as CD8
T-cell responses to virus infection and viral pathogenesis (3, 8).
Studies from our group and others have shown that MyD88
is critical for the induction of the LCMV-specific CD8 T-cell
response (18, 40, 49). Moreover, we have also shown that the
defective CD8 T-cell response to LCMV infection in MyD88
knockout (KO) mice is not due to a total failure of the APC
system because adoptively transferred P14 T-cell receptor
(TCR) transgenic CD8 T cells (expressing a TCR transgene
specific for the LCMV glycoprotein consisting of residues 33 to
41 [GP33-41] epitope) expand and function comparably in both
MyD88 KO and wild-type (WT) mice (49). In the present
study, we used LCMV infection as a model to test whether the
MyD88 signaling pathway plays a role in the activation of
CD4 T cells in response to a natural viral pathogen. Surpris-
ingly, we found that the MyD88 signaling pathway functions
within the CD4 T cells themselves and is essential for normal
CD4 T-cell function, and we further demonstrated that this
MyD88 signaling is independent of IL-1R- and IL-18R-medi-
ated signaling.
MATERIALS AND METHODS
Reagents. The Armstrong strain of LCMV was kindly provided by Liisa K.
Selin (University of Massachusetts Medical School, Worcester, MA) and was
propagated on BHK-21 cells (ATCC) at a low multiplicity of infection ([MOI]
0.01). Viral titers were determined with an immunological focus assay (4). Rat
anti-LCMV nucleoprotein antibody was kindly provided by Demetrius Mosko-
phidis (Medical College of Georgia, Augusta, GA) (4). The DC line DC2.4 was
kindly provided by Kenneth L. Rock (University of Massachusetts Medical
School, Worcester, MA). The CD8 T-cell depletion antibody, clone 2.43 hy-
bridoma (rat immunoglobulin G1 [IgG1]) (41), was obtained from ATCC. CD4
CD25 regulatory T (Treg) cell-depletion antibody, anti-mouse CD25 hybrid-
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oma (clone PC61; rat IgG1 isotype), was obtained from ATCC. Culture super-
natants were collected and purified using protein G columns. To deplete Treg
cells, a single dose of 500 g of purified PC61 or an equivalent amount of a rat
IgG isotype antibody was injected into CD8 T-cell-depleted MyD88 KO mice
via tail vein on day 5 before intracranial LCMV challenge (12, 38, 39, 43). The
efficacy of CD4 CD25 Treg-cell depletion was confirmed by flow cytometry
using allophycocyanin- or phycoerythrin-conjugated anti-mouse CD4 and fluo-
rescein isothiocyanate-conjugated anti-CD25 antibody (clone 7D4) (BD Phar-
Mingen), anti-CD3 and anti-CD28 (clones 145-2C11 and 37.51, respectively; BD
PharMingen).
Mice. TLR2 and MyD88 KO mice were the gift of S. Akira (Osaka University,
Japan). MyD88 KO mice were backcrossed with C57BL/6 mice at least six
generations. The genotypes of the mice were determined by PCR of tail DNA.
Mice were bred and maintained under specific-pathogen-free conditions. Age-
matched C57BL/6 mice (WT control mice), gamma interferon (IFN-) KO mice,
CD8 T-cell-deficient mice, IL-1R1 KO mice, IL-18 KO mice, and TCR-/-
deficient mice were purchased from the Jackson Laboratories (Bar Harbor, ME).
All mice used were 6 to 10 weeks old.
In order to determine whether the TLR-MyD88 pathway plays a role in CD4
T-cell-mediated central nervous system immunopathology, CD8 T cells were
depleted before intracranial infection with LCMV by intraperitoneal injection
with a rat monoclonal antibody against mouse Lyt2, antibody 2.43 (ATCC) (17,
21, 41), on day 5, 2, 0, 2, and 5 relative to intracranial LCMV infection
and then at weekly intervals. The efficacy of CD8 T-cell depletion was confirmed
by flow cytometry using the anti-CD8 antibody (BD PharMingen). For intra-
cranial infection, mice were lightly anesthetized with isoflurane and injected with
30 l of LCMV Armstrong (200 PFU) diluted with phosphate-buffered saline
(PBS). Mice were monitored and weighed daily. The weight loss was calculated
as follows: [(weight after infection  weight before infection)/weight before
infection]  100. For intravenous infection, mice were infected with 200 l of
LCMV Armstrong (5  105 PFU) diluted with minimal essential medium–2%
fetal calf serum (FCS). Animals were housed and experiments were performed
in accordance with animal welfare guidelines.
Viral peptide. The LCMV-specific CD4 T-cell epitope peptide used in this
study was major histocompatibility complex (MHC) class II I-Ab restricted
GP61–80 (34). The peptide was synthesized by the Tufts University peptide core
facility and purified by high-performance liquid chromatography.
Quantitation of CD4 T-cell response by intracellular staining for IFN- and
tumor necrosis factor alpha (TNF-). Methods used to isolate mononuclear cells
(MNC) from the brain have been described previously (50). Briefly, mice were
perfused through the right ventricle with 10 ml of PBS prior to tissue removal.
Brain tissues were mashed through a 70-m-pore-size strainer in RPMI medium
with 10% FCS. The resulting cell suspensions were centrifuged, and the pellet
was resuspended in a 38% Percoll solution (Pharmacia), layered onto a 68%
Percoll solution, and centrifuged at 600  g for 20 min at 4°C. MNC were
recovered from the gradient interface and washed twice with complete RPMI
medium before use.
To prepare conventional DCs ([cDCs] CD11c DCs), both WT and MyD88
KO mice were subcutaneously injected with 2.5  105 B16-Flt3L melanoma cells
in 200 l of PBS to increase the frequencies of cDCs. On day 10 after injection,
spleens were collected and CD11c DCs were enriched using anti-CD11c mag-
netic beads (Miltenyi Biotec). Enriched cDCs, together with a control DC line,
DC2.4, were infected with LCMV WE strain at a multiplicity of infection of 0.5
(32, 50) because DCs are not sensitive to the infection of LCMV Armstrong (13).
At 48 h postinfection, DCs were collected, and 5  104 cDCs were cocultured
with 5 105 purified LCMV-immune (day 10 postinfection) CD4 T cells for 5 h
in the presence of brefeldin A (1 g/ml; BD PharMingen). The expression of
IFN- was examined by intracellular cytokine staining (ICS).
ICS was performed as described previously (33). Briefly, cells were cultured in
96-well flat-bottom plates at a density of 106 cells/well in 200 l of RPMI 1640
medium supplemented with 10% FCS, recombinant human IL-2 (hIL-2; 20
U/ml; Roche), and brefeldin A (1 g/ml; BD PharMingen) in the presence or
absence of the LCMV-specific CD4 epitope peptide GP61–80 (GLKGP-
DIYKGVYQFKSVEFD) at a concentration of 4 g/ml. Cells were also cultured
with phorbol myristate acetate (100 ng/ml) and ionomycin (500 ng/ml). After 5 h
of culture, the cells were harvested, washed once in PBS, and surface stained with
allophycocyanin-conjugated monoclonal rat antibody specific to mouse CD4
(clone RM4-5; BD PharMingen). After being washed, the cells were stained for
intracellular cytokines by using a Cytofix/Cytoperm kit (BD PharMingen) ac-
cording to manufacturer’s instructions. Phycoerythrin-conjugated monoclonal
rat antibodies specific to murine IFN- (clone XMG1.2; BD PharMingen) or
fluorescein isothiocyanate-conjugated monoclonal rat antibody to murine TNF-
(clone MP6-XT22; BD PharMingen) and the isotype control (rat IgG1) were
used to identify cytokine-positive cells. Samples were acquired on a BD-LSR-II
flow cytometer (Becton Dickinson). Data were analyzed with FlowJo software.
To test whether the MyD88 signaling pathway affects TCR-dependent CD4
T-cell activation, splenocytes were stimulated with immobilized anti-CD3 (20
g/ml) and soluble anti-CD28 (100 ng/ml). After incubation for 72 h, the levels
of IFN- in the supernatants were determined using an enzyme-linked immu-
nosorbent assay (BD PharMingen) according to the manufacturer’s instructions.
Quantitative analysis of virus-specific CD4 T cells by tetramer staining.
I-Ab-restricted tetramer complexed with LCMV CD4 epitope peptide GP66–77
(DIYKGVYQFKSV) or control peptide were kindly provided by the NIH Tet-
ramer Core Facility (Emory Vaccine Center, Atlanta, GA). Single-cell suspen-
sions prepared from spleen and brain were stained with I-Ab tetramer. After the
samples were stained at 37°C for 3 h in RPMI medium–2% FCS (48), cells were
washed once with PBS and stained with anti-CD4 allophycocyanin-conjugated
rat monoclonal antibody with 1% bovine serum albumin and 0.2% sodium azide.
After being stained for 30 min at 4°C, cells were washed twice with PBS, fixed in
PBS containing 4% formaldehyde, and analyzed on a BD-LSR-II flow cytometer
(Becton Dickinson). Data were analyzed with FlowJo software.
Purification of CD4 T cells and adoptive transfer experiment. Spleens and
mesenteric lymph nodes collected from naïve mice were pooled, and a single-cell
suspension was prepared. Erythrocytes were lysed with red blood cell lysis buffer
(Sigma). CD4 T cells were purified using a CD4 T-cell isolation kit (mouse
CD4 T cells are isolated by depletion of non-CD4 T cells) following the
instructions supplied by manufacturer (Miltenyi Biotec, Auburn, CA). The purity
of CD4 T cells was always 	90% as assessed by flow cytometry and with no
detectable CD8 T cells. A total of 5106 purified CD4 T cells were adoptively
transferred into recipient mice via tail vein injection. One day after adoptive
transfer, recipients were infected with LCMV Armstrong.
Construction of mouse MyD88 lentivirus. The gene coding for mouse MyD88
was amplified by using reverse transcription-PCR. Total RNA was prepared
from normal C57BL/6 mouse splenocytes using a Qiagen RNeasy Mini kit. The
primers were designed according to the sequence deposited in the GenBank
database (accession no. NM_010851): forward primer, 5
-AGCACCGGTGCC
TGCCATGTCTGCGGGAGAC-3
 (underlined AgeI restriction site); reverse
primer, 5
-ATTGCCCTTGGCTCTAGAGGGTCATCTGTAGGGCAGGG-3

(underlined XbaI restriction site). The PCR product was first ligated directly into
pcDNA3-V5/His-TOPO as described by the manufacturer (Invitrogen). Plasmid
DNA containing MyD88 sequence was isolated, and the insert DNA was excised
by AgeI and XbaI digestion. Enhanced green fluorescent protein (EGFP) in
lentiviral vector pUb-EGFP-Thy1.1 (kindly provided by Zhibin Chen, University
of Miami Miller School of Medicine) was excised by AgeI/XbaI digestion and
replaced with the mouse MyD88 gene. This construct was transformed into Stbl2
competent cells. The final MyD88 lentiviral construct, named pUb-MyD88/
Thy1.1, was confirmed by restriction analysis and DNA sequencing (Tufts Uni-
versity DNA Core Facility). Expression of MyD88 is under the control of ubiq-
uitin-C promoter. Additional plasmids necessary for generating lentivirus including
cytomegalovirus-Eco (rodent specific) and Rous sarcoma virus-Rev were the gift of
Z. Chen. All plasmids were extracted using a Qiagen Hi-Speed Maxi kit.
Production and quantification of MyD88 lentivirus. Protocols provided by
Chen and also described by Dull et al. (9) were followed, with some modifica-
tions. Briefly, 5  106 of the GP2-293 packaging cells (BD) were plated into
10-cm2 petri dishes. GP2-293 is an HEK-293-based packaging cell line that stably
expresses the viral gag and pol genes. When cells were 90% to 95% confluent,
they were transfected using a calcium chloride transfection protocol. The fol-
lowing amounts of plasmids were used per dish: 20 g of pUb-MyD88/Thy1.1 or
control pUb-EGFP/Thy1.1 and 10 g of both Rous sarcoma virus-Rev and
cytomegalovirus-Eco. At 4 h after transfection, medium was removed, cells were
washed with PBS, and 10 ml of Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% heat-inactivated fetal bovine serum was added. At 36 to
48 h after transfection, culture supernatants were collected and spun at low speed
(2,000 rpm for 10 min). The titers of the MyD88 lentivirus and control lentivirus
were determined by transducing NIH 3T3 fibroblasts seeded in a 12-well plate (5
 104 cells per well) with serially diluted lentivirus-containing supernatants
supplemented with 6.0 g/ml polybrene (Sigma). Thy1.1 was used as a marker to
determine the concentration of the lentivirus. After incubation for 48 h, the
expression of Thy1.1 was analyzed by FACS staining with anti-Thy1.1 antibody
(BD). The concentration of lentivirus was calculated on the basis of the number
of Thy1.1-positive cells and expressed as infectious virus particle (titer is defined
as the number of infectious virus particles/ml).
Purification and transduction of MyD88 KO CD4 T cells with MyD88 len-
tivirus and adoptive transfer and analysis of MyD88 lentivirus-transduced
MyD88 KO CD4 T cells in vivo. Naïve MyD88 KO CD4 T cells were purified
from MyD88 KO female mice using a CD4 T-cell purification kit as described
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above (Miltenyi Biotec, Auburn, CA). Cells were activated and transduced with
either MyD88 lentivirus pUb-MyD88/Thy1.1 or control lentivirus pUb-EGFP/
Thy1.1 following the protocol kindly provided by Laurence Turka and col-
leagues. Briefly, purified naïve MyD88 KO CD4 T cells (	93% purity as
checked by FACS staining) were plated into 24-well plates at 2  106 cells per
well and activated with 1 M ionomycin, 3 ng/ml of phorbol myristate acetate,
and 10 units/ml of recombinant hIL-2 (Roche) for 24 h. After activation, medium
was removed, and 1.0 ml of lentivirus supernatants together with 6 g/ml of
polybrene and 10 units/ml of hIL-2 was added, and cells were spun at 2,200 rpm
for 90 min at 22°C. After centrifugal infection, cells were washed once with
DMEM–10% FCS, and then 1.0 ml of DMEM–10% FCS and 10 units/ml of
hIL-2 were added, and cells were incubated an additional 48 h. The efficiency of
transduction of CD4 T cells was determined by the expression of Thy1.1. A
total of 5  106 of the transduced CD4 T cells were adoptively transferred into
TCR-/-deficient female mice via tail vein injection. After 24 h, mice were
challenged intravenously with 5  105 PFU of LCMV Armstrong. At day 9
postinfection, the CD4 T-cell responses in recipients were examined by restimu-
lation of donor CD4 T cells in vitro with LCMV-specific CD4 epitope peptide
GP61–80, and the expression of IFN- was analyzed by ICS as described above.
Histopathology study. On day 12 after intracranial infection with LCMV, two
mice from each group (WT, IL-1R1 KO, and MyD88 KO mice) were euthanized,
and their brains were fixed with Bouin’s fixative reagent. The brain tissues were
routinely embedded in paraffin and sectioned at 6 m. Brain sections were
stained with hematoxylin and eosin.
Statistical analysis. Data were evaluated using a two-tailed Student’s t test.
Results were expressed as means  standard deviation. P values of 0.05 were
regarded as significant.
RESULTS
LCMV-induced weight loss is MyD88 dependent but is IL-
1R1/IL-18R independent. Intracranial infection of immuno-
competent mice with LCMV leads to fatal CD8 T-cell-medi-
ated LCM while intracranial infection of CD8 T-cell-deficient
mice with LCMV causes wasting disease, characterized by
CD4 T cell-mediated weight loss (7, 10, 14, 29). Our previous
studies have demonstrated that CD8 T cells are abnormal in
MyD88 KO mice (49). Our initial experiments showed that
intracranial LCMV infection in MyD88 KO mice induced a
delayed lethal meningitis compared to WT mice (data not
shown), suggesting that, although impaired, the CD8 T-cell
response could still be detrimental to the host in an intracra-
nial infection model. In the present study, we eliminated CD8
T cells and then determined the role of the MyD88 adaptor
molecule in the CD4 T-cell response to LCMV infection.
Interestingly, after depletion of CD8 T cells and intracranial
infection with LCMV, WT mice started losing weight at about
day 7 postinfection, and at peak they lost up to 30% of their
body weight (Fig. 1A). In contrast, CD8 T-cell-depleted
MyD88 KO mice did not show any symptoms of disease.
We used CD8 T-cell-deficient mice to validate our obser-
vations. These mice lack CD8 T cells but have normal CD4
T cells. After intracranial infection with LCMV, CD8 T-cell
KO mice steadily lost weight (Fig. 1A), which is consistent with
previous findings that CD4 T cells are responsible for weight
loss (10). Taken together, these studies suggested that MyD88
is involved in LCMV-induced CD4 T-cell responses and the
CD4 T-cell-dependent wasting disease.
MyD88 is an essential adaptor molecule for several recep-
tors including all TLRs (except TLR3) and both the IL-1R and
the IL-18R-mediated signaling pathways (1, 44). To determine
whether IL-1R and IL-18R rather than TLRs were responsible
for MyD88-dependent wasting disease, IL-1R1 KO and IL-
18R KO mice were depleted of CD8 T cells and infected
intracranially with LCMV. CD8 T-cell-depleted IL-1R1 KO
and IL-18R KO mice exhibited weight loss compared to CD8
T-cell-depleted MyD88 KO mice (Fig. 1B). Thus, these studies
demonstrated that neither IL-1R1 nor IL-18R alone played a
major role in LCMV-induced MyD88-dependent wasting disease.
Intracranial LCMV infection induced severe inflammation
in the brains of WT and IL-1R1 KO mice but not in MyD88
KO mice. To determine whether the observed clinical symp-
FIG. 1. LCMV-induced weight loss is MyD88 dependent but IL-
1R1 or IL-18R independent. All mice, except CD8 T-cell and TCR-
/ KO mice, were injected with monoclonal antibody 2.43 to deplete
CD8 T cells, as described in Materials and Methods. (A) Groups of
WT (n  29), MyD88 KO (n  24), and CD8 T-cell-deficient (n 
15) mice were intracranially infected with LCMV Armstrong as de-
scribed above. Body weight loss was compared. In total, 1 of 29 WT
mice died on day 12 postinfection, and 3 of 15 CD8 KO mice died
between day 10 and day 13 postinfection. (B) WT (n  10), MyD88
KO mice (n  5), IL-1R1 KO (n  15), and IL-18R KO mice (n  18)
were intracranially infected with LCMV Armstrong. Body weight loss
was compared. A representative of three to five experiments is shown.
(C) A total of 5  106 purified naïve WT or MyD88 KO CD4 T cells
were adoptively transferred into TCR-/ KO recipients; the next day,
recipients were followed by intracranial LCMV infection. The weight
loss was recorded and compared.
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toms were related to inflammation in the brain, histopatho-
logic analysis was performed. After depletion of CD8 T cells
and intracranial infection with LCMV, the brains of WT and
IL-1R1 KO mice demonstrated a prominent infiltration of
MNC compared to the brains of uninfected WT mice. The
severity of the meningitis was assessed based on the accumu-
lation of inflammatory cells in the meninges of the brains. The
meninges of intracranially infected WT and IL-1R1 KO mice
exhibited prominent signs of inflammation (Fig. 2). In marked
contrast, there was little, if any, inflammation in the brains of
MyD88 KO mice (Fig. 2).
LCMV Armstrong is usually cleared within 2 weeks postin-
fection in WT mice (28, 31, 33), and depletion of CD8 T cells
leads to persistent LCMV infection (20, 47). We have mea-
sured the virus titers in mice depleted of CD8 (see Fig. 4F).
Consistent with previous studies (25), our CD8-depleted WT
mice were unable to clear LCMV Armstrong infection for up
to 30 days postinfection. MyD88 KO CD8-depleted mice had
even higher levels of virus.
CD4 T-cell activation in response to intracranial LCMV
infection is MyD88 dependent but IL-1R1-/IL-18R indepen-
dent. It has been demonstrated that the intracranially LCMV-
induced wasting disease is mediated by LCMV-specific CD4
T cells that infiltrate the central nervous system (7, 14, 21).
LCMV-specific CD4 T cells express both IFN- and TNF-
(17, 36), which we used as functional indicators to assess the
CD4 T-cell response. To determine whether the functionality
of CD4 T cells correlates with the clinical symptoms (Fig. 1A
and B) and the pathological changes in the brain (Fig. 2), WT,
MyD88 KO, IL-1R1 KO, and IL-18R KO mice were depleted
of CD8 T cells and infected intracranially with LCMV. The
state of CD4 T-cell activation in the brain as well as in the
spleen and peripheral blood was determined by intracellular
staining of IFN- and FACS analysis after restimulation in
vitro with the LCMV-specific dominant CD4 epitope peptide,
GP61–80 (5, 46). In MyD88 KO mice, the LCMV-specific CD4

T-cell IFN- response in all the tissues tested was severely
impaired compared to WT mice (Fig. 3A to D). In contrast,
LCMV infection induced comparable CD4 T-cell IFN- and
TNF- responses in WT, IL-1R1 KO, and IL-18R KO mice
(Fig. 3A to D and data not shown). Taken together, these
results correlated with the clinical symptoms and demonstrated
that an IL-1R/IL-18R-independent but MyD88-dependent sig-
naling pathway is essential for activation of the CD4 T cells in
response to LCMV infection.
To determine if the MyD88 molecule is involved in the
development of LCMV-specific CD4 T-cell responses,
LCMV-specific CD4 T cells were directly visualized using
LCMV-specific MHC class II-restricted tetramer reagent
(NIH Tetramer Core Facility). LCMV infection in WT mice
induced a robust CD4 T-cell response (Fig. 3E and F). Sur-
prisingly, LCMV infection in MyD88 KO mice did not induce
LCMV-specific CD4 T-cell responses. Therefore, these re-
sults demonstrated that the MyD88 protein is essential for the
development of LCMV-specific CD4 T-cell responses.
MyD88 KO mice have normal APC function in response to
LCMV infection. After being engaged by antigen-presenting
cells (APCs), naïve CD4 T cells undergo clonal expansion
FIG. 2. LCMV-induced brain histological change is MyD88 dependent but IL-1R1 or IL-18R independent. Mice were depleted of CD8 T cells with
monoclonal antibody 2.43 and were intracranially infected with LCMV Armstrong as described in Materials and Methods. Two mice from each of WT,
MyD88 KO, and IL-1R1 KO groups were sacrificed on day 12 postinfection; brains were sectioned and stained with hematoxylin and eosin. WT mouse
brain injected intracranially with PBS was a negative control. The severity of the meningitis was assessed based on the accumulation of the inflammatory
cells in the meninges of the brains (two arrows in each image point to the thickness of the meninges, representing the amount of the accumulated
inflammatory cells). Representative sections of cerebral cortex, with a focus on meninges/meningitis, are shown. The relative severity of the meningitis
was as follows: uninfected WT mice (), LCMV-infected WT mice (), IL-1R1 KO mice (), and MyD88 KO mice ().
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and then differentiate into functional subsets of either Th1 or
Th2 cells (15, 42). Several studies have demonstrated that the
MyD88 adaptor protein is involved in the activation of APCs
(15). To determine how MyD88 is involved in the regulation of
CD4 T-cell responses to LCMV, the following experiments
were conducted. First, we wanted to determine whether the
impaired CD4 T-cell response in MyD88 KO mice to LCMV
infection is due to the failure of the APC system. Purified naive
FIG. 3. LCMV-induced CD4 T-cell activation is MyD88 dependent but IL-1R1 and IL-18R independent. WT (n  9), MyD88 KO (n  9),
IL-1R1 KO (n  6), and IL-18R KO (n  5) mice were intracranially infected with LCMV as described in Materials and Methods. Between days
13 to 15 postinfection, CD4 T-cell responses in the brain, spleen, and peripheral blood lymphocytes were examined by restimulation in vitro with
LCMV CD4 T-cell epitope peptide GP61–80 and intracellular staining for IFN- (A to C) or TNF- (D). The average percentages of the total CD4

T cells and CD4 T cells expressing IFN- (CD4 IFN- T cells) in brain, spleen, and peripheral blood lymphocytes are shown in panels A to
C. Results are representative of at least four experiments for WT and MyD88 KO mice and two experiments for IL-1R1 and IL-18R KO mice.
(E and F) WT (n  3) and MyD88 KO mice (n  3) were intracranially infected with LCMV. At day 9 postinfection, spleen and brain were
collected. LCMV-specific CD4 T cells in spleen and brain were directly visualized using I-Ab-restricted CD4 tetramer complexed with LCMV
GP66–77 peptide or a control peptide. Results shown are the average from three mice per group. , P  0.05.
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B6/Thy1.1 CD4 T cells were transferred into CD8 T-cell-
depleted MyD88 KO and C57BL/6 WT mice followed by in-
travenous infection with LCMV Armstrong (Fig. 4A). At day 8
postinfection, the function of transferred CD4 T cells was
determined by ICS. Thy1.1 was used as a marker for the trans-
ferred T cells. We found, surprisingly, that in response to
LCMV infection, WT donor CD4 (Thy1.1) T cells pro-
duced IFN- regardless of the expression of MyD88 in the
recipient APC system (Fig. 4A). These results suggested
that MyD88 KO mice have a competent APC system.
To further examine if MyD88 expression in APCs could
affect APC function in terms of activation of CD4 T cells, we
directly compared the antigen presentation capacity of both
WT and MyD88 KO APCs ex vivo. To prepare APCs, cDCs
were isolated from both WT and MyD88 KO mice. cDCs were
infected with the WE strain of LCMV, and at 48 h postinfec-
tion, LCMV-infected cDCs were cocultured for 5 h with WT
CD4 T cells (isolated from day 10 LCMV-infected WT mice).
The LCMV-infected DC2.4 DC line was included as a positive
control and prepared as described previously (32, 50). The
expression of IFN- on the cocultured CD4 T cells was mon-
itored by ICS. Interestingly, both WT and MyD88 KO cDCs
were able to present LCMV-specific CD4 epitopes to activate
WT CD4 T cells (Fig. 4B). The same experiment was also
conducted with cDCs infected in vivo and isolated from day 2.5
LCMV-infected WT and MyD88 KO mice. Similarly, MyD88
KO cDCs were capable of activating WT CD4 T cells com-
pared to their WT control cDCs (data not shown). Collectively,
FIG. 4. MyD88 signaling pathway intrinsically regulates the activation of naive CD4 T cells. (A) A total of 5  105 purified naïve B6/Thy1.1
CD4 T cells were adoptively transferred into CD8 T-cell-depleted WT and MyD88 KO recipients (n  3 for each group), followed by
intravenous infection with LCMV. At day 10 postinfection, CD4 T-cell responses (IFN- expression) in the spleens were analyzed by ICS after
restimulation with LCMV CD4 epitope peptide GP61–80 or phorbol myristate acetate (PMA) and ionomycin. Cells were gated on CD4
 Thy1.1
T cells (donor origin for both MyD88 KO and WT recipients). (B) LCMV-infected CD11c cDCs or DC2.4 cells were cocultured with purified
LCMV-immune (day 10 postinfection) CD4 T cells. The expression of IFN- was analyzed using ICS. (C and D) A total of 5  106 purified naïve
WT or MyD88 KO CD4 T cells were adoptively transferred into TCR-/ KO mice, followed by intracranial LCMV infection. At day 20
postinfection, the function of CD4 T cells in spleen was examined by restimulating CD4 T cells with LCMV GP61–80 peptide for 5 h (C) or with
immobilized anti-CD3 antibody for 72 h (D). The expression of IFN- was measured by intracellular IFN- staining. Results shown are the average
from three mice per group. (E) Both MyD88 KO and WT mice were depleted of CD8 T cells with monoclonal antibody 2.43 as described above.
CD4 CD25 regulatory Treg cells in MyD88 KO mice were depleted with PC61 antibody or an equivalent amount of a rat IgG isotype antibody.
Mice were intracranially infected with LCMV Armstrong as described above. Body weight loss was compared for up to 9 days postinfection.
(F) CD8-depleted mice failed to clear LCMV Armstrong infection. Mice were depleted of CD8 T cells as described in Material and Methods and
intracranially infected with LCMV Armstrong. At day 30 postinfection, virus titers in spleens and brains were determined. Results shown are the
average from three to five mice per group.
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using both in vivo and ex vivo methods, we demonstrated that
APCs in MyD88 KO mice are comparable to APCs from WT
mice in their ability to activate WT CD4 T cells. Thus, these
studies demonstrated that the absence of MyD88 signaling in
APCs does not account for the impaired CD4 T-cell function
in MyD88 KO mice in response to LCMV infection. These
results suggested that MyD88 might be intrinsically involved in
CD4 T-cell functional maturation.
Expression of MyD88 in CD4 T cells is critical to their
functional maturation and to inducing weight loss. To deter-
mine how MyD88 is involved in the regulation of CD4 T cells
in response to LCMV, naïve CD4 T cells were purified from
both MyD88 KO and WT mice. A total of 5  106 purified
naïve CD4 T cells from both strains were adoptively trans-
ferred into TCR-/ KO recipients (deficient of both CD4
and CD8 T cells) via tail vein injection (Fig. 4C). The fol-
lowing day, TCR-/ KO recipients were challenged by intra-
cranial LCMV infection. Consistent with results from the
LCMV-infected WT mice (Fig. 1A and B), CD4 T cells from
WT naïve mice mediated weight loss (Fig. 1C). The function of
transferred CD4 T cells was examined by ICS. WT CD4 T
cells had normal function; i.e., they responded to stimulation
with LCMV GP61–80 peptide by producing IFN- (Fig. 4C). In
contrast, MyD88 KO CD4 T cells failed to produce IFN- in
response to LCMV GP61–80 peptide restimulation. Both trans-
ferred WT and MyD88 KO CD4 T cells responded to anti-
CD3 stimulation (Fig. 4D), suggesting that MyD88 KO CD4
T cells were capable of IFN- expression when their TCR was
cross-linked ex vivo although these cells failed to respond to
LCMV infection in vivo. Thus, we conclude that the incompe-
tent CD4 T-cell response in MyD88 KO mice to LCMV is not
due to the defective antigen presentation capacity of MyD88
KO APCs. Their defect is the inability to produce IFN- and
TNF- in response to LCMV.
In addition, it has been reported that CD4 CD25 Treg
cells play a role in the regulation of MyD88-dependent CD4
T-cell activation to model antigens (38, 39). To further deter-
mine whether Treg cells are responsible for the defective
CD4 T-cell response in MyD88 KO mice following acute
LCMV infection, Treg cells in MyD88 KO mice were depleted
before LCMV infection with the commonly used monoclonal
antibody PC61 (12, 38, 39, 43). Treg-cell depletion was con-
firmed by flow cytometry. The percentage of CD25 CD4 T
cells significantly decreased compared to their counterpart in
the isotype control antibody-treated MyD88 KO mice
(0.76%  0.03% versus 8.19%  1.27%, respectively). Deple-
tion of CD4 CD25 Treg cells did not induce the wasting
disease in MyD88 KO mice following intracranial LCMV in-
fection (Fig. 4E), suggesting that Treg cells do not play a
decisive role in the defective CD4 T-cell response in MyD88
KO mice.
Together, these observations suggested that the MyD88 sig-
naling pathway is intrinsically involved in the functional mat-
uration of CD4 T cells and independent of Treg cells.
Expression of MyD88 in MyD88 KO CD4 T cells restores
CD4 T-cell function. Having shown that MyD88 could be
intrinsically involved in the responsiveness of CD4 T cells, we
next determined if reconstitution of MyD88 KO CD4 T cells
with the MyD88 gene could restore function. We constructed
an MyD88-expressing lentivirus, pUb-MyD88/Thy1.1 (Fig.
5A). MyD88 and control lentivirus efficiently transduced both
NIH 3T3 cells and MyD88 KO CD4 T cells (Fig. 5B and C).
When MyD88 KO CD4 T cells were transduced with the
MyD88-expressing lentivirus to rescue MyD88 activity, the
CD4 T cells were able to respond to LCMV infection by
expression of IFN- (Fig. 5D). In contrast, when MyD88 KO
CD4 T cells were transduced with a control lentivirus,
MyD88 KO CD4 T cells remained unable to respond to
LCMV infection (Fig. 5D). Furthermore, when TCR-/ KO
recipients received MyD88-reconstituted (lentiviral rescue)
MyD88 KO CD4 T cells, they produced significantly more
IgG2a anti-LCMV antibody (Fig. 5E) than TCR-/ KO re-
cipients that received control lentivirus-transduced KO CD4
T cells in response to LCMV. Therefore, lentiviral gene trans-
fer of mouse MyD88 into MyD88 KO CD4 T cells was suf-
ficient to restore function for both IFN- production and T
helper function for the antibody response, demonstrating the
critical role of MyD88 in T cells in the response to a viral
infection.
DISCUSSION
A number of recent studies have highlighted the importance
of MyD88 in the regulation of the inflammatory responses in
innate immune cells, but its role in the regulation of the adap-
tive immune response and immunopathology is poorly defined
(6, 23, 24). How do MyD88-dependent signals affect T-cell
responses? The current paradigm for explaining the regulation
of T cells by MyD88 is that TLR-dependent activation of
MyD88 in DCs leads to their maturation as APCs with the
secretion of immune-modulated chemokines and cytokines
and upregulation of the MHC and other costimulatory mole-
cules and, in turn, plays a central role in stimulation of the
T-cell responses (15, 16). Our present study reveals an unap-
preciated role of MyD88 signaling in the regulation of the
CD4 T-cell response to virus infection. We demonstrate that
the MyD88 molecule expressed in the CD4 T cells themselves
controls the development of virus-specific CD4 T cells fol-
lowing challenge with a natural murine viral pathogen, LCMV.
The MyD88 adaptor protein is not only essential for TLR
signaling (with the exception of TLR3) but is also a critical
adaptor protein in IL-1R- and IL-18R-dependent signaling (1,
2, 44). By directly comparing the impact of the MyD88-, IL-
1R1-, and IL-18R-mediated signaling pathways on the activa-
tion of a virus-specific CD4 T-cell response, we demonstrated
that the defect is likely TLR specific since the IL-1R1- and
IL-18R-dependent signaling pathways do not play a major role
in the activation and differentiation of CD4 T cells to LCMV
infection. A recent publication also indicated that the IL-18-
dependent signaling pathway is not involved in the LCMV-
specific CD4 T-cell response (30). Thus, our study outlines
the importance of the MyD88 signaling pathway in the regu-
lation of CD4 T-cell responses to a natural murine viral
pathogen. Our studies are consistent with a recent publication
by Larosa et al. (26), in which the authors demonstrated that
the expression of MyD88 in CD4 T cells is essential for the
production of IFN- in CD4 T cells and for the protection of
mice from Toxoplasma gondii infection.
Although MyD88 is critically involved in the induction of
chemokines and cytokines from APCs or other cells (2, 15, 37,
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44, 49), our study has demonstrated that naïve WT CD4 T
cells have comparable function when transferred into MyD88
KO recipients compared to those in WT recipients (Fig. 4A).
Furthermore, our ex vivo study has shown that MyD88 KO
APCs (cDCs) are comparable to WT APCs in their ability to
present LCMV-specific CD4 epitopes to activate LCMV-im-
mune WT CD4 T cells. Collectively, these results suggest that
the defective CD4 responses to LCMV infection in MyD88
KO mice are not due to a failure of the APC system (Fig. 4A
to C).
Our adoptive transfer experiments with purified CD4 T
cells indicate that the defective CD4 T-cell response is re-
lated to an intrinsic defect in CD4 T cells. When WT or
MyD88 KO naïve CD4 T cells were transferred into TCR-/
KO recipients, only WT CD4 T cells had the capacity to
mediate weight loss and to express IFN- (Fig. 1C, 4D). Fur-
thermore, TCR-/ KO recipients that received WT CD4 T
cells produced significantly more IgG2a isotype anti-LCMV
antibody, a characteristic of a Th1-type immune response, in
comparison to TCR-/ KO recipients receiving MyD88 KO
CD4 T cells. Importantly, we provided evidence that the
function of MyD88 KO CD4 T cells can be restored by
FIG. 5. Reconstituted MyD88 KO CD4 T cells function with MyD88-expressing lentivirus. (A) Diagram of mouse MyD88-expressing
lentivirus. (B) Viral titer was determined by transduction of NIH 3T3 cells for 48 h and flow cytometry analysis of the expression of Thy1.1. Cells
were infected with lentivirus and stained with anti-Thy1.1 antibody (black line) or with anti-Thy1.1 isotype control antibody (gray fill). (C) Purified
MyD88 CD4 T cells were transduced with lentivirus for 48 h, and the expression of Thy1.1 was examined. Cells were infected with lentivirus and
were doubly stained with anti-Thy1.1 and anti-CD4 antibodies (black line) or with anti-Thy1.1 isotype control antibody and anti-CD4 antibodies
(gray fill). (D) A total of 5  106 of lentivirus-transduced MyD88 KO CD4 T cells were adoptively transferred into TCR-/-deficient mice, and
recipients were challenged with LCMV Armstrong (intravenously). At day 9 postinfection, mesenteric lymph nodes were collected, and the
function of CD4 T cells was analyzed by in vitro restimulation with either medium or LCMV-specific CD4 epitope peptide GP61–80. The
expression of IFN- was measured by intracellular IFN- staining. (E) Serum was collected at day 9 postinfection, and the levels of LCMV-specific
antibody were measured by using an enzyme-linked immunosorbent assay. Serum collected from LCMV-infected (day 9) WT mice was used as
the control.
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transducing MyD88 KO CD4 T cells with an MyD88-express-
ing lentivirus (Fig. 5). Therefore, our studies demonstrate that
MyD88 in T cells is responsible for activation of CD4 T cells
in response to LCMV infection.
How MyD88 in CD4 T cells regulates virus-specific CD4
T-cell responses is currently not clear. TLRs are expressed in T
cells, including conventional CD4 T cells (CD4  T cells),
at least at the mRNA level (19, 22). Certain types of TLR
ligands can directly activate T cells in the absence of APCs,
suggesting that TLRs, including TLR2, play a role in the acti-
vation of T cells (11, 19). A recent publication has provided
direct evidence that MyD88 is responsible for CpG DNA-
induced direct activation of naïve CD4 T cells and that phos-
phatidylinositol 3-kinase is involved in this MyD88-dependent
activation pathway (11). While our observations have some
similarities to these studies, there are some fundamental dif-
ferences between our model and other models that make our
findings regarding the TLR adaptor protein, MyD88, and its
role in the regulation of the virus-specific CD4 T-cell re-
sponses distinct. Previous studies have used nonreplicating an-
tigens or TLR ligands to evaluate the activation of CD4 T
cells. In our study, we used a natural murine viral pathogen,
LCMV. After infection of the target cells with LCMV, endo-
genously synthesized LCMV GP (which contains the dominant
CD4 T-cell epitope GP61–80) needs to be processed by the
APCs to form a complex with MHC class II I-Ab molecules and
to be presented on the APC surface in order to stimulate a
CD4 T-cell response (35). Moreover, virus-induced activation
of T cells involves the dynamic interaction of APCs and T cells
in the immunological synapse, which plays a major role in the
activation of CD4 T cells. In contrast, other TLR ligands,
including tripalmitoyl-Cys-Ser-Lys-Lys-Lys-Lys (TLR1/TLR2
ligand) and CpG (TLR9 ligand), activate CD4 T cells in a
ligand receptor-specific but antigen-unspecific interaction
manner (11, 19). Thus, viruses like LCMV could use a distinc-
tive mechanism to activate MyD88-dependent CD4 T-cell
activation.
The role of the Treg cells in a virus-induced immune re-
sponse has recently attracted increased attention (38, 39). It
has been demonstrated that Treg cells suppress both expansion
and functional maturation of the effector T-cell response, and
it has been reported that Treg cells repress both the primary
and secondary virus-induced immune responses (45). How-
ever, the role of Treg cells in the LCMV-induced immune
responses is uncertain (43). Pasare et al. showed that depletion
of Treg cells with anti-CD25-depleting monoclonal antibody
(clone PC61) restored CD4 T-cell responses to ovalbumin in
MyD88 KO mice, suggesting that Treg cells contribute to the
defective CD4 T-cell response to model antigens in MyD88
KO mice (39). In the present study, depletion of Treg cells had
little effect on LCMV-induced CD4 T-cell responses and
weight loss in MyD88 KO mice (Fig. 4E). Thus, our study
suggests that the impaired CD4 T-cell responses in MyD88
KO mice in response to LCMV infection are unlikely to be due
to the action of Treg cells.
In summary, these studies reveal for the first time that the
expression of MyD88 in CD4 T cells is essential for the
activation of CD4 T cells in response to a natural murine viral
pathogen. Our studies and studies of others demonstrated that
the effects of MyD88 on T-cell responses are independent of
APCs and Treg cells (11, 26). Furthermore, we demonstrated
that MyD88 expression in CD4 T cells is required for the
production of both IFN- and TNF- as well as helper cell
activity for antibody production in response to virus.
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